China
Clinical and regulatory developments in breast cancer for multiple HER-2-targeting antibody-drug conjugates from Chinese firms look set to up the competition for Enhertu.
The acceleration of commercial health insurance was included in national development plans for 2026 released by the Chinese government in the recent “Two Sessions” policy meetings, and appears key for the next generation of innovative drugs to achieve domestic success.
Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Multinationals showed up with open arms for partnering with Chinese developers at the recent BIOCHINA meeting, but there were signs approaches are changing and firms are now looking beyond straight licensing.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
The Spanish company has set up shop in Shanghai to be closer to current and future dermatology partners.
Clinical Data Readout: Jacobio Pharmaceuticals and AstraZeneca's JAB-23E73, a pan-KRAS inhibitor, stands out among its peers as the first to report preliminary Phase I results after completing the dose escalation phase of a China-based clinical study.
China has granted a world-first approval to a cAMP-biased GLP-1R agonist, Sciwind's ecnoglutide, for weight management, following convincing Phase III results.
Qilu’s bifunctional combo of PD-1 and CTLA-4 antibodies hits its marks in a Phase III cervical cancer trial, while Lynk’s JAK1 inhibitor logs similar win in atopic dermatitis.
UCB is paying $1bn-plus for global rights to Antengene's ATG-201, an anti-CD19/CD3 T-cell engager, as it looks to build its strength in immunology.
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JAK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
China’s National Medical Products Administration grants global-first approval to oral JAK/ROCK inhibitor for adult primary and secondary myelofibrosis.
Clinical Data Readout: With a median follow-up of 6.5 months, updated findings from a Phase I/II study of DB-1311 (BNT324) in heavily pretreated mCRPC patients worldwide showed a median radiographic progression-free survival of 11.3 months and a median overall survival of 22.5 months.
Amid a wider domestic market downturn, Beijing Health Guard’s three Phase III trials for two of its HPV vaccine candidates were suspended in January and February due to overdue payments to sites.
Sichuan Biokin Pharmaceutical’s iza-bren hit the co-primary endpoints of OS and PFS in a Phase III clinical study in Chinese patients with triple-negative breast cancer in the second and later-line settings.
2026 has already seen several major new funding rounds for Chinese biopharma ventures, including a $70m financing for CAR-T specialist Oricell and a $40m Angel round for ADC specialist Tosun.
Chinese company expands its amylin-targeting portfolio in obesity with fast-paced plans for progressing clinical trials in the US and finding partners.
Kangtai has decided to terminate the original plan for a roughly $400m partnership with AstraZeneca announced in March 2025 which was expected to establish the UK major's first vaccine manufacturing site in China.
Scrip takes a look at the next generation of innovation in obesity medicines coming out of China and key assets originated in the country set to enter Phase III this year.